Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...
Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday.
Stoke Therapeutics advances TANGO ASO for Dravet, with Zorevunersen Phase 3 data showing seizure reduction and a delayed 2027 ...
Commercial launch in Switzerland anticipated in H2 2026Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces ...
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is one of the stocks under $1 that will explode. Sangamo Therapeutics, Inc.’s ...
Shares of Cyclerion Therapeutics climbed after the company entered an agreement to integrate Medsteer's technology into its lead program in development for treatment-resistant depression. The stock ...
Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.
Tango Therapeutics ( (TNGX)) has shared an announcement. On January 2, 2026, Tango Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed Sung H. Lee as an ...
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback